A world-first national mass drug administration program using ivermectin has drastically reduced scabies cases and secondary skin infections across Solomon Islands and Fiji, according to a new study published in Nature Health. Led by the World Scabies Program at the Murdoch Children’s Research Institute and involving researchers from the Kirby Institute at UNSW Sydney, the research demonstrates that coordinated public health interventions can successfully control the parasitic skin disease at scale.
Mass Drug Administration Drives Down Scabies Prevalence
According to the study, implementing national mass drug administration campaigns yielded steep declines in disease rates across both Pacific nations. In Solomon Islands, where the entire population received two annual rounds of treatment, scabies prevalence dropped from 23.2 percent down to 3.9 percent. Researchers noted a corresponding decline in impetigo, a bacterial skin infection, falling from 9.2 percent to 1.6 percent over the same period.
Fiji achieved similar public health gains following a single nationwide round of treatment. Scabies prevalence in Fiji nearly halved, moving from 6.2 percent down to 3.4 percent, while impetigo rates decreased from 4.3 percent to 1.2 percent within 12 months, according to study findings.
Did you know? Scabies affects more than 600 million people globally each year. The World Health Organization officially recognized it as a neglected tropical disease in 2017 to spur global control efforts.
Reaching Vulnerable Populations Through Targeted Strategies
The campaign distributed more than 2.5 million doses of ivermectin, a safe and widely used antiparasitic treatment. Data showed that scabies and impetigo decreased across all age groups, including young children who typically experience the highest burden of disease. Moderate-to-severe cases also declined substantially, according to the research team.
Achieving high coverage in densely populated urban environments required adapting delivery methods. According to Murdoch Children’s Research Institute Professor Andrew Steer, teams delivered treatments through workplaces, schools, and community gatherings to ensure broad access. However, researchers noted that further measures remain necessary to tackle persistent transmission in children under five, where prevalence stayed above 10 percent despite the mass treatment.
Implications for Global Public Health Policy
Scabies causes intense itching, skin damage, and secondary infections linked to Strep A bacteria, which can lead to severe long-term complications such as kidney damage and potentially rheumatic heart disease. The new findings provide critical evidence to support the integration of scabies control into broader public health frameworks, according to Murdoch Children’s Research Institute Dr. Susanna Lake.
To assist other nations facing high disease burdens and limited healthcare resources, the World Health Organization released a new scabies control guide featuring contributions from Murdoch Children’s Research Institute researchers including Dr. Lake, Professor Steer, and Dr. Daniel Engelman. The manual outlines practical steps for estimating disease burden, delivering treatments, and establishing monitoring systems.
Pro Tip: Public health officials looking to replicate these outcomes can consult the World Health Organization’s official scabies management guidelines for standardized frameworks on local disease estimation and community-level treatment delivery.
Frequently Asked Questions
What is mass drug administration for scabies?
Mass drug administration involves treating an entire defined population with an antiparasitic medication like ivermectin simultaneously, regardless of whether individual symptoms are present, to rapidly lower community transmission rates.
Why are secondary skin infections linked to scabies dangerous?
Scabies damages the skin barrier, facilitating secondary infections caused by Strep A bacteria. These infections can lead to serious downstream health conditions, including kidney disease and rheumatic heart disease.
How was the mass drug administration funded and supported?
The World Scabies Program was established in 2019 following a $10 million contribution from the Macquarie Group Foundation, with additional financial backing provided by the Australian Government.
What are your thoughts on implementing large-scale parasite control programs? Share your perspective in the comments below, or subscribe to our newsletter for the latest public health research updates.
Keep reading